Shukra Pharma. Q1 FY27 Results (NSE: SHUKRAPHAR)
Signal: Margins at cyclical peak
| Metric | Value | YoY | QoQ |
|---|---|---|---|
| Revenue | ₹23.52 Cr | +336.4% | +272.0% |
| EBIT | ₹18.6 Cr | +1033.5% | |
| Net profit | ₹12.96 Cr | +1159.3% | |
| EPS | ₹0.3 | +1400.0% | |
| EBIT margin | 83.68% |
P&L walk
Revenue rebounded to ₹2352.23 lakh, +336.4% YoY and +272.0% QoQ, driving EBIT of ₹1860.13 lakh and EBITDA margin of 83.68%; employee costs rose +140.5% YoY but much slower than revenue, supporting substantial fixed-cost absorption, while PAT of ₹1295.85 lakh was operating-led despite other income falling 51.4%.
Research and educational content only. Not investment advice.